Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Dermapharm Holding SE, DE000A2GS5D8

Dermapharm Holding SE, DE000A2GS5D8

20.11.2019 - 07:32:30

Dermapharm Holding SE continues to drive the company's growth in the third quarter of 2019

as of today.


Key financial figures for the first nine months of 2019 year-on-year

in EUR millions 9M 2019 9M 2018 Change         Group sales 517.6 429.0 +20.7% Branded pharmaceuticals and other healthcare products 276.2 249.5 +10.7% Parallel import business 185.1 179.5 +3.1% Herbal extracts 56.3 - -         Adjusted¹ Group EBITDA 133.1 106.4 +25.1% Branded pharmaceuticals and other healthcare products 113.8 102.1 +11.5% Parallel import business 7.2 7.8 -7.7% Herbal extracts 16.2 - - Adjusted¹ EBITDA margin (in %) 25.7 24.8 +0.9pp Branded pharmaceuticals and other healthcare products 41.2 40.9 +0.3pp Parallel import business 3.9 4.4 -0.5pp Herbal extracts 28.8 - -         Group EBITDA 124.6 102.6 +21.4% EBITDA margin (in %) 24.1 23.9 +0.2pp  

¹ 9M 2019 EBITDA adjusted for EUR 8.5 million in non-recurring expenses and provisions. 9M 2018 EBITDA adjusted for non-recurring expenses in the amount of EUR 3.8 million.

Company profile:

Dermapharm - Pharmaceutical Excellence "Made in Germany"

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company's integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm has more than 900 marketing authorisations (Arzneimittelzulassungen) for approximately 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company's core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm's business model also includes a parallel import business, which operates under the "axicorp" brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2018. In the "Herbal Extracts" segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.

With a consistent R&D strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimised its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.


Investor Relations Britta Hamberger Phone: +49 (0)89 - 64186-233 Fax: +49 (0)89 - 64186-165 e-mail: ir@dermapharm.com cometis AG Claudius Krause Phone: +49 (0)611 - 205855-28 Fax: +49 (0)611 - 205855-66 e-mail: ir@dermapharm.com  


20.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Dermapharm Holding SE Lil-Dagover-Ring 7 82031 Grünwald

Germany Phone: +49 (0)89 64 86-0 E-mail: ir@dermapharm.com Internet: ir.dermapharm.de ISIN: DE000A2GS5D8 WKN: A2GS5D Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange EQS News ID: 916455   End of News DGAP News Service

916455  20.11.2019 

@ dgap.de